These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30378353)

  • 1. [Advances on genotoxic impurities of sulfonate esters in pharmaceuticals].
    Liu X; Li C; Han H; Zhang W; Chen D
    Se Pu; 2018 Oct; 36(10):952-961. PubMed ID: 30378353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control and analysis of alkyl esters of alkyl and aryl sulfonic acids in novel active pharmaceutical ingredients (APIs).
    Elder DP; Teasdale A; Lipczynski AM
    J Pharm Biomed Anal; 2008 Jan; 46(1):1-8. PubMed ID: 18053672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Forced degradation and impurity profiling: recent trends in analytical perspectives.
    Jain D; Basniwal PK
    J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification, control strategies, and analytical approaches for the determination of potential genotoxic impurities in pharmaceuticals: a comprehensive review.
    Reddy AV; Jaafar J; Umar K; Majid ZA; Aris AB; Talib J; Madhavi G
    J Sep Sci; 2015 Mar; 38(5):764-79. PubMed ID: 25556762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of chromatographic methods for the determination of genotoxic impurities in cloperastine fendizoate.
    García A; Rupérez FJ; Ceppa F; Pellati F; Barbas C
    J Pharm Biomed Anal; 2012 Mar; 61():230-6. PubMed ID: 22226040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control and analysis of alkyl and benzyl halides and other related reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs).
    Elder DP; Lipczynski AM; Teasdale A
    J Pharm Biomed Anal; 2008 Nov; 48(3):497-507. PubMed ID: 18657926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of genotoxic impurities in pharmaceutical development.
    Bercu JP; Dobo KL; Gocke E; McGovern TJ
    Int J Toxicol; 2009; 28(6):468-78. PubMed ID: 19966139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid and simultaneous determination of sulfonate ester genotoxic impurities in drug substance by liquid chromatography coupled to tandem mass spectrometry: comparison of different ionization modes.
    Guo T; Shi Y; Zheng L; Feng F; Zheng F; Liu W
    J Chromatogr A; 2014 Aug; 1355():73-9. PubMed ID: 24997109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug substances presented as sulfonic acid salts: overview of utility, safety and regulation.
    Elder DP; Snodin DJ
    J Pharm Pharmacol; 2009 Mar; 61(3):269-78. PubMed ID: 19222899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of potentially genotoxic impurities in crotamiton active pharmaceutical ingredient by gas chromatography.
    Kalauz A; Kapui I
    J Pharm Biomed Anal; 2022 Feb; 210():114544. PubMed ID: 34968997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control and analysis of hydrazine, hydrazides and hydrazones--genotoxic impurities in active pharmaceutical ingredients (APIs) and drug products.
    Elder DP; Snodin D; Teasdale A
    J Pharm Biomed Anal; 2011 Apr; 54(5):900-10. PubMed ID: 21145684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low level determination of 4-amino-2-ethoxy-cinnamic acid and its ethyl ester in a drug substance and its formulation prototypes by HPLC-UV-DAD.
    Soman A; Jacob S; Swanek F
    J Chromatogr Sci; 2009 Apr; 47(4):315-9. PubMed ID: 19406019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in the risk assessment of potentially genotoxic impurities in pharmaceutical drug substances.
    Humfrey CD
    Toxicol Sci; 2007 Nov; 100(1):24-8. PubMed ID: 17656486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification, isolation, characterization, and UHPLC quantification of potential genotoxic impurities in linagliptin.
    Huang Y; Lu H; Zhang F; Min C
    J Sep Sci; 2018 Nov; 41(21):3985-3994. PubMed ID: 30155968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall impact of the regulatory requirements for genotoxic impurities on the drug development process.
    Giordani A; Kobel W; Gally HU
    Eur J Pharm Sci; 2011 May; 43(1-2):1-15. PubMed ID: 21420491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitive derivatization methods for the determination of genotoxic impurities in drug substances using hyphenated techniques.
    Raman NV; Prasad AV; Reddy KR
    J Pharm Biomed Anal; 2014 Feb; 89():276-81. PubMed ID: 24316427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process.
    Liu DQ; Chen TK; McGuire MA; Kord AS
    J Pharm Biomed Anal; 2009 Sep; 50(2):144-50. PubMed ID: 19427156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of genotoxic impurities of aromatic aldehydes in pharmaceutical preparations by high performance liquid chromatography after derivatization with N-Cyclohexyl-4-hydrazino-1,8-naphthalenediimide.
    Xu Z; Reheman A; Lu Z; Yu S; Sun Z; You J
    J Chromatogr A; 2024 May; 1722():464866. PubMed ID: 38581976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simple and sensitive method to analyze genotoxic impurity hydrazine in pharmaceutical materials.
    Wang J; Yang S; Zhang K
    J Pharm Biomed Anal; 2016 Jul; 126():141-7. PubMed ID: 27208624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The utility of sulfonate salts in drug development.
    Elder DP; Delaney E; Teasdale A; Eyley S; Reif VD; Jacq K; Facchine KL; Oestrich RS; Sandra P; David F
    J Pharm Sci; 2010 Jul; 99(7):2948-61. PubMed ID: 20112423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.